Lung Cancer Clinical Trials

• Adult male/female patients ≥18 years old at the time of signing the informed consent form (ICF).

• Histologic or cytologic diagnosis of advanced NSCLC, stage IV (defined by the 8th edition of the Tumor Node Metastasis \[TNM\] classification), with no EGFR sensitizing (activating) mutation or ALK translocation, and who have not received prior systemic treatment for metastatic NSCLC. In those patients in whom the pleural or pericardial effusion is the only location of metastatic disease, confirmation of its malignant etiology is required.

• At least 1 radiographically measurable lesion according to response evaluation criteria in solid tumors (RECIST) 1.1.

• Known status of PD-L1 expression.

• Performance based on the Eastern Cooperative Oncology Group (ECOG) performance status ≤1.

• Adequate hepatic, renal, hematologic, endocrine, and coagulation function.